The PPARα–leukotriene B4 pathway to inflammation control
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPARalpha. Because PPARalpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B4 in the liver. Thus PPARalpha offers a new route to the development of anti- or pro-inflammatory reagents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FFAs act as PPAR agonists facilitating translocation to the nucleus and dimerization to RXR [77,78].”
From Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation (2021) · cites this paper as [77]
In the citing paper
“PPAR-α is involved in the regulation of pro-inflammatory genes, mainly by limiting cytokine expression.[109]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [109]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Self-citation
Research works printed but not linked: 6
- Ford-Hutchinson, A. W. Crit. Rev. Immunol. 10, 1–11 (1990).
- Desvergne, B. & Wahli, W. in Inducible Transcription Vol. 1 (ed. Bæuerle, P.) 142–176 (Birkhäuser, Boston, 1995).
- Greene, M. E. et al. Gene Expr. 4, 281–299 (1995).
- Schmidt, A. et al. Mol. Endocrinol. 6, 1634–1641 (1992).
- Yu, K. et al. J. Biol. Chem. 270, 23975–23983 (1995). · DOI · Paper page
- Peters, J. M. et al. Mol. Pharmacol. 50, 67–94 (1996).
Cited by
Items 601–700 of 1,001
Sartippour, M. R., & Renier, G. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.1.104 · Cited by 52
Coregulatory Proteins in Nuclear Hormone Receptor Action
Edwards, D. P. (1998) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60936-x · Cited by 57
Bouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Kita, R., Takamatsu, S., Kimura, T., Kokuryu, H., Osaki, Y., & Tomono, N. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1831-0 · Cited by 53
Discovery of small-molecule candidates against inflammatory bowel disease
Bai, R., Jie, X., Yao, C., & Xie, Y. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111805 · Cited by 52
Assogna, M., Casula, E. P., Borghi, I., Bonnì, S., Samà, D., Motta, C., Lorenzo, F. D., D’Acunto, A., Porrazzini, F., Minei, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200426 · Cited by 53
From Food to Genes: Transcriptional Regulation of Metabolism by Lipids and Carbohydrates
Bravo-Ruiz, I., Medina, M. Á., & Martínez-Poveda, B. (2021) · Nutrients · doi:10.3390/nu13051513 · Cited by 61
Li, L., Beauchamp, M.-C., & Renier, G. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00203-4 · Cited by 59
Expression of 5-lipoxygenase in pulmonary artery endothelial cells
Zhang, Y., Walker, J. L., Huang, A., Keaney, J. F., Clish, C. B., Serhan, C. N., & Loscalzo, J. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3610267 · Cited by 51
Lipids and the immune response.
Yaqoob, P. (1998) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-199803000-00003 · Cited by 54
Peroxisome Proliferator-Activated Receptors and the Cardiovascular System
Chen, Y. E., Fu, M., Zhang, J., Zhu, X., Lin, Y., Akinbami, M. A., & Song, Q. (2003) · Vitamins and hormones · doi:10.1016/s0083-6729(03)01005-7 · Cited by 53
Species differences in peroxisome proliferation; mechanisms and relevance
Choudhury, A. I., Chahal, S., Bell, A. R., Tomlinson, S. R., Roberts, R. A., Salter, A. M., & Bell, D. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(99)00237-7 · Cited by 50
Peroxisome Proliferator-Activated Receptor-α Activation Inhibits Langerhans Cell Function
Dubrac, S., Stoitzner, P., Pirkebner, D., Elentner, A., Schoonjans, K., Auwerx, J., Saeland, S., Hengster, P., Fritsch, P., Romani, N., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4362 · Cited by 47
PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis
Yang, Y., Gocke, A. R., Lovett‐Racke, A. E., Drew, P. D., & Racke, M. K. (2008) · PPAR Research · doi:10.1155/2008/546753 · Cited by 50
“[19] demonstrated that lack of PPAR-α activity increases inflammatory responses.”
BackgroundSubchronic Effects of Perfluorooctanesulfonate Exposure on Inflammation in Adult Male C57BL/6 Mice
Dong, G., Zhang, Y., Zheng, L., Liang, Z., Jin, Y., & He, Q. (2012) · Environmental Toxicology · doi:10.1002/tox.20642 · Cited by 49
“Inflammation is a local immune response to foreign molecules, infection and injury (Devchand et al., 1996).”
BackgroundNuclear receptors in regenerating liver and hepatocellular carcinoma
Vacca, M., Degirolamo, C., Massafra, V., Polimeno, L., Mariani‐Costantini, R., Palasciano, G., & Moschetta, A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.06.025 · Cited by 51
Martin, H. L., Mounsey, R. B., Sathe, K., Mustafa, S., Nelson, M. C., Evans, R. M., & Teismann, P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.058 · Cited by 47
“In addition, PPARs have been shown to regulate inflammatory processes (Devchand et al., 1996; Ricote et al., 1999; Delerive et al., 2001).”
BackgroundPeroxisome proliferator‐activated receptors and inflammation: take it to heart
Smeets, P., Planavila, A., Vusse, G. J., & van Bilsen, M. (2007) · Acta Physiologica · doi:10.1111/j.1748-1716.2007.01752.x · Cited by 52
“The anti-inflammatory properties of PPARs were first observed in PPARa knock-out mice showing a prolonged inflammatory response following an earswelling test (Devchand et al. 1996).”
BackgroundWiesenberg, I., Chiesi, M., Missbach, M., Spanka, C., Pignat, W., & Carlberg, C. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13286-5 · Cited by 56
“…B4, 8-hydroxy-eicosatetraenoic acid) are not only potent inflammatory mediators but also PPAR ligands has generated the interesting hypothesis that activation of PPARs might be involved in the control and limitation of inflammatory reactions (Devchand et al., 1996; Kliewer et al., 1997).”
InfluentialPeroxisome Proliferator Activated Receptors
Genolet, R., Michalik, L., & Wahli, W. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_22 · Cited by 49
Self-citationPeroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation
Hunt, M. J., & Tyagi, S. C. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00152.2002 · Cited by 49
Johnson, T. E. (1999) · Endocrinology · doi:10.1210/en.140.7.3245 · Cited by 49
Cui, X., Kawashima, H., Barclay, T. B., Peters, J. M., Gonzalez, F. J., Morgan, E. T., & Strobel, H. W. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38770-1 · Cited by 49
Self-citationTreating acne with antibiotic-resistant bacterial colonization
Tzellos, T., Zampeli, V., Makrantonaki, E., & Zouboulis, C. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.553192 · Cited by 49
Mechanisms of action, chemical characteristics, and model systems of obesogens
Griffin, M. D., Pereira, S. R., DeBari, M. K., & Abbott, R. D. (2020) · BMC Biomedical Engineering · doi:10.1186/s42490-020-00040-6 · Cited by 52
Liu, J., Sahin, C., Ahmad, S., Magomedova, L., Zhang, M., Jia, Z., Metherel, A. H., Orellana, A. J., Poda, G. I., Bazinet, R. P., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abo1857 · Cited by 55
Haeggström, J. Z., Kull, F., Rudberg, P., Tholander, F., & Thunnissen, M. M. G. M. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00051-5 · Cited by 57
Natural ligands of nuclear receptors have conserved volumes
Bogan, A. A., Cohen, F. E., & Scanlan, T. S. (1998) · Nature Structural & Molecular Biology · doi:10.1038/1372 · Cited by 48
85-kDa cPLA2plays a critical role in PPAR-mediated gene transcription in human hepatoma cells
Han, C. L., Demetris, A. J., Michalopoulos, G. K., Shelhamer, J. H., & Wu, T. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00305.2001 · Cited by 53
PPARβ/δ Protects Against Experimental Colitis Through a Ligand-Independent Mechanism
Hollingshead, H. E., Morimura, K., Adachi, M., Kennett, M. J., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9644-9 · Cited by 48
“Administration of PPARα ligands can inhibit TNF-α and metalloproteinase secretion from lipopolysaccharide (LPS)activated monocytes [12, 13] and PPARα-null mice also exhibit prolonged inflammation in response to leukotriene B4 [ 14 ].”
BackgroundSelf-citationCOX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?
Colville‐Nash, P., & Gilroy, D. W. (2000) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(00)00074-5 · Cited by 49
Involvement of 5-lipoxygenase in programmed cell death of cancer cells
Maccarrone, M., Catani, M. V., Finazzi‐Agrò, A., & Melino, G. (1997) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400255 · Cited by 48
Lee, H., Nam, G., Kim, S. H., & Lee, S. H. (2005) · Experimental Dermatology · doi:10.1111/j.0906-6705.2005.00386.x · Cited by 55
Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?
Puddu, P., Puddu, G. M., & Muscari, A. (2003) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00565-x · Cited by 51
Maresin-1 resolution with RORα and LGR6
Im, D. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101034 · Cited by 48
Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis
Racke, M. K., Gocke, A. R., Muir, M. T., Diab, A., Drew, P. D., & Lovett‐Racke, A. E. (2006) · Journal of Nutrition · doi:10.1093/jn/136.3.700 · Cited by 48
“PPARα-deficient mice have abnormally prolonged responses to inflammatory stimuli such as arachidonic acid and leukotrienes (40).”
BackgroundPan-PPAR Modulation Effectively Protects APP/PS1 Mice from Amyloid Deposition and Cognitive Deficits
Kummer, M. P., Schwarzenberger, R., Sayah-Jeanne, S., Dubernet, M., Walczak, R., Hum, D. W., Schwartz, S., Axt, D., & Heneka, M. T. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8743-4 · Cited by 47
Leukotriene Receptors: Crucial Components in Vascular Inflammation
Bäck, M. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.187 · Cited by 47
Lipid soluble vitamins in gene regulation
Carlberg, C. (1999) · BioFactors · doi:10.1002/biof.5520100202 · Cited by 52
Eicosanoids: lipid mediators of inflammation in transplantation
Rocha, P. N., Plumb, T. J., & Coffman, T. M. (2003) · Springer Seminars in Immunopathology · doi:10.1007/s00281-003-0132-4 · Cited by 49
“LTB 4 may also act as a ligand for peroxisome proliferator-activated receptor α (PPARα), which has been shown to have anti-inflammatory effects [ 9 ].”
BackgroundThe human peroxisome in health and disease: The story of an oddity becoming a vital organelle
Vamecq, J., Cherkaoui‐Malki, M., Andreoletti, P., & Latruffe, N. (2013) · Biochimie · doi:10.1016/j.biochi.2013.09.019 · Cited by 47
“PPARa reduces the inflammatory response period by inducing genes catabolizing leukotriene B4 (LTB4) in peroxisomes [59].”
BackgroundRodríguez‐Carrio, J., Alpéri, M., López, P., Ballina‐García, F. J., & Suárez, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159573 · Cited by 48
Targeting leukotriene B4in inflammation
Gennaro, A. D., & Haeggström, J. Z. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.843671 · Cited by 47
Fang, X., Dillon, J. S., Hu, S., Harmon, S. D., Yao, J., Anjaiah, S., Falck, J. R., & Spector, A. A. (2006) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2006.05.002 · Cited by 47
Pleiotropic effects of fibrates
Chinetti, G., Fruchart, J., & Staels, B. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0053-x · Cited by 51
Peroxisome proliferator-activated receptor-β as a target for wound healing drugs
Tan, N. S., Michalik, L., Desvergne, B., & Wahli, W. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.1.39 · Cited by 46
“PPARα is also thought to accelerate the catabolism of inflammation-derived fatty acids, thus decreasing the duration of inflammatory reactions [17].”
BackgroundSelf-citationNuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Peroxisome proliferator‐activated receptors as therapeutic target for cancer
Wang, Y., Lei, F., Lin, Y., Han, Y., Yang, L., & Tan, H. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17931 · Cited by 48
Cabré, M. F., Solman, S. A., & Núñez, M. N. (2010) · Climatic Change · doi:10.1007/s10584-009-9737-5 · Cited by 45
Peroxisomes and Disease - an Overview
Schrader, M., Delille, H. K., & Bonekamp, N. A. (2006) · International Journal of Biomedical Science · doi:10.59566/ijbs.2006.2308 · Cited by 45
Boden, S. E., Schweizer, S., Bertsche, T., Düfer, M., Drews, G., & Safayhi, H. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23129-1 · Cited by 45
Signaling mechanisms in renal compensatory hypertrophy revealed by multi-omics
Kikuchi, H., Chou, C., Yang, C., Chen, L., Jung, H. J., Park, E., Limbutara, K., Carter, B. C., Yang, Z., Kun, J. F., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38958-9 · Cited by 47
The elusive endogenous adipogenic PPARγ agonists: Lining up the suspects
Hallenborg, P., Petersen, R. K., Kouskoumvekaki, I. A., Newman, J. W. I., Madsen, L., & Kristiansen, K. (2015) · Progress in Lipid Research · doi:10.1016/j.plipres.2015.11.002 · Cited by 48
Paukkeri, E., Leppänen, T., Sareila, O., Vuolteenaho, K., Kankaanranta, H., & Moilanen, E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707477 · Cited by 48
“A clear evidence of British Journal of Pharmacology (2007) 152 1081–1091 the immunomodulating effects of PPARa was unveiled in 1996, when PPARa-null mice were shown to present a prolonged inflammatory reaction in response to leukotriene B4 as compared to wild-type animals (Devchand et al., 1996).”
BackgroundMurray, J., Ward, C., O’Flaherty, J. T., Dransfield, I., Haslett, C., Chilvers, E. R., & Rossi, A. G. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705265 · Cited by 44
“Role of PPARa in LTB4-mediated survival of human neutrophils It is now well recognised that LTB4 is a potent activating ligand for PPARa (Devchand et al., 1996).”
BackgroundInfluentialKojo, H., Fukagawa, M., Tajima, K., Suzuki, A., Fujimura, T., Aramori, I., Hayashi, K.-I., & Nishimura, S. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.93.347 · Cited by 44
Maruyama, S., Kato, K., Kodama, M., Hirono, S., Fuse, K., Nakagawa, O., Nakazawa, M., Miida, T., Yamamoto, T., Watanabe, K., et al. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.87 · Cited by 44
Castrillo, A., Mojena, M., Hortelano, S., & Boscá, L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102472200 · Cited by 47
Wahli, W., Devchand, P. R., Jpenberg, A. I., & Desvergne, B. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4861-4_19 · Cited by 44
Self-citationHanaka, H., Shimizu, T., & Izumi, T. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3610505 · Cited by 44
Devchand, P. R., Hihi, A. K., Perroud, M., Schleuning, W.-D. D., Spiegelman, B. M., & Wahli, W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23341 · Cited by 44
Self-citationMetabolic Signals Trigger Glucose-Induced Inactivation of Maltose Permease in Saccharomyces
Jiang, H., Medintz, I. L., Zhang, B., & Michels, C. A. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.3.647-654.2000 · Cited by 44
Holen, E., Espe, M., Andersen, S. M., Taylor, R. G., Aksnes, A., Mengesha, Z. T., & Araujo, P. W. (2014) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2014.02.004 · Cited by 43
Fibrates: Therapeutic potential for diabetic nephropathy?
Kouroumichakis, I., Παπάνας, Ν., Zarogoulidis, P., Liakopoulos, V., Maltezos, E. S., & Mikhailidis, D. P. (2012) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2011.12.007 · Cited by 46
Alaoui-El-Azher, M., Wu, Y., Havet, N., Israël, A., Lilienbaum, A., & Touqui, L. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12329-2 · Cited by 43
Wang, Y., Wagner, K. M., Morisseau, C. H. P., & Hammock, B. D. (2021) · Journal of Pain Research · doi:10.2147/jpr.s241893 · Cited by 43
Marks, F., Fürstenberger, G., & Müller‐Decker, K. (1999) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59945-3_4 · Cited by 43
François, M., Richette, P., Tsagris, L., Fitting, C., May, C. L., Benallaoua, M., Tahiri, K., & Corvol, M. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21728 · Cited by 43
Peroxisome proliferator‐activated receptors in squamous cell carcinoma and its precursors
Nijsten, T. E. C., Geluyckens, E., Colpaert, C., & Lambert, J. R. (2005) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2005.00345.x · Cited by 43
Leukotrienes modulate cytokine release from dendritic cells
Józefowski, S., Biedroń, R., Bobek, M., & Marcinkiewicz, J. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02241.x · Cited by 46
Willy, P. J., & Mangelsdorf, D. J. (1998) · Elsevier eBooks · doi:10.1016/b978-012312411-1/50011-1 · Cited by 50
Gervois, P. P., Fruchart, J., & Staels, B. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00376.x · Cited by 48
The role of leukotrienes in immunopathogenesis of rheumatoid arthritis
Yousefi, B., Jadidi‐Niaragh, F., Azizi, G., Hajighasemi, F., & Mirshafiey, A. (2013) · Modern Rheumatology · doi:10.1007/s10165-013-0861-8 · Cited by 45
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 48
“Although most of the antiinflammatory effects of PPARs can be explained by transrepression, anti-inflammatory activities based on direct gene regulation through the PPARa-leukotriene B4 pathway [18,19] or by regulating IkBa expression [20] have also been described.”
BackgroundZheng, S., Ren, X., Tingting, H., Chen, Y., Qiu, H., Liu, W., & Hu, Y. (2017) · Metabolism · doi:10.1016/j.metabol.2017.09.001 · Cited by 42
Pagliari, F., Marafioti, M. G., Genard, G., Candeloro, P., Viglietto, G., Seco, J. C., & Tirinato, L. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.578964 · Cited by 43
“In this regard, PPARs can also be stimulated by AA-derived metabolites (prostaglandins and leukotrienes), that, as previously reported, are mediators of the inflammatory responses (Devchand et al., 1996; Ricote et al., 1998; Lee et al., 2003; Varga et al., 2011).”
BackgroundPu, Y., Cheng, C. K., Zhang, H., Luo, J., Wang, L., Tomlinson, B., & Huang, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21970 · Cited by 47
Lee, H., Rao, J. S., Ertley, R. N., Chang, L., Rapoport, S. I., & Bazinet, R. P. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0582-1 · Cited by 42
“They can act as a ligand for transcriptional regulators, including peroxisomal proliferator activator receptors ( Devchand et al. 1996 ), and hepatic nuclear factor-4α (Hertz et al. 1998), as a ligand for the prostaglandin receptors (Kuehl and Humes 1972; Kuehl et al. 1970), and can increase glutamatergic NMDA signali…”
InfluentialRetractedGenovese, T., Esposito, E., Mazzon, E., Crisafulli, C., Paterniti, I., Paola, R. D., Galuppo, M., Bramanti, P., & Cuzzocrea, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.018 · Cited by 42
Banga, A., Greder, L. V., Dutton, J. R., & Slack, J. M. W. (2013) · Gene Therapy · doi:10.1038/gt.2013.50 · Cited by 42
Biology of senescent liver peroxisomes: role in hepatocellular aging and disease.
Youssef, J., & Badr, M. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107791 · Cited by 42
Maeda, T., & Kishioka, S. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)85013-7 · Cited by 44
Stier, H., Fahimi, H. D., Völkl, A., Baumgart‐Vogt, E., Veldhoven, P. P. V., & Mannaerts, G. P. (1998) · Differentiation · doi:10.1046/j.1432-0436.1998.6410055.x · Cited by 47
Berger, J. P., Patel, H. V., Woods, J. W., Hayes, N. S., Parent, S. A., Clemas, J. A., Leibowitz, M. D., Elbrecht, A., Rachubinski, R. A., Capone, J. P., et al. (2000) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(00)00211-2 · Cited by 51
Human Leukotriene B 4 Ω- Hydroxylase ( CYP4F3 ) Gene: Molecular Cloning and Chromosomal Localization
Kikuta, Y., KATO, M., Yamashita, Y., Miyauchi, Y., Tanaka, K. J., Kamada, N., & Kusunose, M. (1998) · DNA and Cell Biology · doi:10.1089/dna.1998.17.221 · Cited by 42
“Peroxisome proliferator-activated re¬ ceptor (PPAR) recognition elements, which were reported to be involved in the catabolism of LTB4 (Devchand et al, 1996), likewise were not located in the 5' flanking region of the CYP4F3 gene.”
Leaver, M. J., Wright, J., & George, S. G. (1998) · Marine Environmental Research · doi:10.1016/s0141-1136(97)00070-6 · Cited by 42
Poynter, M. E., & Daynes, R. A. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1525 · Cited by 44
5-Lipoxygenase Inhibitors for the Treatment of COPD
Kilfeather, S. (2002) · CHEST Journal · doi:10.1378/chest.121.5_suppl.197s · Cited by 42
Broos, J. Y., van der Burgt, R. T. M., Konings, J., Rijnsburger, M., Werz, O., de Vries, H. E., Giera, M., & Kooij, G. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02981-w · Cited by 41
Crisafulli, S. G., Brajkovic, S., Mis, M. S. C., Parente, V., & Corti, S. P. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0532-4 · Cited by 43
Meng, F.-G., Zhang, X., Liu, S.-X., Wang, Y., & Zeng, T. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109176 · Cited by 41
Barretto, S. A., Lasserre, F., Huillet, M., Régnier, M., Polizzi, A., Lippi, Y., Fougerat, A., Person, E., Bruel, S., Bétoulières, C., et al. (2021) · Microbiome · doi:10.1186/s40168-021-01050-9 · Cited by 42
Self-citationCytochrome P4504f, a potential therapeutic target limiting neuroinflammation
Sehgal, N., Agarwal, V., Valli, R. K., Joshi, S. D., Antonovič, L., Strobel, H. W., & Ravindranath, V. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.025 · Cited by 46
Rakkestad, K. E., Holme, J. A., Paulsen, R. E., Schwarze, P. E., & Becher, R. (2009) · Inhalation Toxicology · doi:10.3109/08958370903019885 · Cited by 43
“Moreover, LTB 4 has been reported to stimulate resolution of inflammation via PPAR (Devchand et al., 1996).”
BackgroundMinge, C. E., Ryan, N. K., der Hoek, K. H. V., Robker, R. L., & Norman, R. J. (2005) · Biology of Reproduction · doi:10.1095/biolreprod.105.043729 · Cited by 44
DHEA: A Biologist's Perspective
Hornsby, P. J. (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb02941.x · Cited by 43
Paciello, F., Pisani, A., Rolesi, R., Escarrat, V., Galli, J., Paludetti, G., Grassi, C., Troiani, D., & Fetoni, A. R. (2021) · Antioxidants · doi:10.3390/antiox10081188 · Cited by 43
Gaudreault, É., & Gosselin, J. (2007) · Viral Immunology · doi:10.1089/vim.2006.0099 · Cited by 40
Patel, N. S. A., Paola, R. D., Mazzon, E., Britti, D., Thiemermann, C., & Cuzzocrea, S. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146191 · Cited by 40
Águila, M. B., Silva, S. P. S., Pinheiro, A. R., & Mandarim‐de‐Lacerda, C. A. (2004) · Journal of Hypertension · doi:10.1097/00004872-200405000-00013 · Cited by 45
Metadata
- Authors
- Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W.
- Affiliations
- University of Lausanne (CH)
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1996-11
- Volume
- 384
- Issue
- 6604
- Pages
- 39-43
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1671834350
- Cited by
- 1,345
- References
- 43
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 14 · 2023: 21 · 2022: 9 · 2021: 38 · 2020: 30 · 2019: 23 · 2018: 21 · 2017: 24 · 2016: 23 · 2015: 22 · 2014: 43 · 2013: 34 · 2012: 49
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- PPARα, leukotriene B4, inflammation, transcription factor activation, fatty acid oxidation, lipid mediators, chemotaxis, anti-inflammatory agents, liver, feedback regulation
- MeSH terms
- Adaptation, Physiological, Animals, Cells, Cultured, Fatty Acids, Female, Gene Expression Regulation, HeLa Cells, Humans, Inflammation, Leukotriene B4, Ligands, Liver, Male, Oxidation-Reduction, Plasmids, Pyrimidines, Time Factors, Transcription Factors, Transfection, Chloramphenicol O-Acetyltransferase, Arachidonic Acid, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.